Lilly Announces Positive Phase 3 Results for Inluriyo in Advanced Breast Cancer

Eli Lilly and Company +3.78% Pre

Eli Lilly and Company

LLY

954.52

946.15

+3.78%

-0.88% Pre

Eli Lilly and Company has announced new data from its breast oncology portfolio and pipeline to be featured at the upcoming San Antonio Breast Cancer Symposium (SABCS), scheduled for December 9-12, 2025. The company will present updated results from the Phase 3 EMBER-3 trial evaluating Inluriyo (imlunestrant), an estrogen receptor antagonist, alone and in combination with Verzenio (abemaciclib) in patients with ER+, HER2- advanced or metastatic breast cancer. The late-breaking oral presentation will include a pre-specified interim overall survival analysis, as well as updates on progression-free survival and time to chemotherapy. Additionally, a poster presentation will provide exploratory analysis results regarding early changes in circulating tumor DNA and their correlation to clinical outcomes. Further results from the Phase 3 monarchE trial, exploring outcomes by nodal status for Verzenio plus endocrine therapy in HR+, HER2- high-risk early breast cancer, will also be presented. Data from the Phase 1/2 PIKALO-1 trial of Lilly's investigational pan-mutant-selective PI3Kα inhibitor, which is advancing to Phase 3, will be shared as well. All results are scheduled for presentation at SABCS 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eli Lilly and Company published the original content used to generate this news brief via PR Newswire (Ref. ID: DE31094) on November 24, 2025, and is solely responsible for the information contained therein.
This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.